Neumora Therapeutics, Inc. - 8-K Filing
Neumora Therapeutics reports favorable pre-clinical toxicology results for NMRA-215 and plans to submit an IND in Q4 2026 (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $NMRA
More Regulatory news
- Carter Bankshares, Inc. - 8-K Filing
- Marvell Technology, Inc. - 8-K Filing
- VISHAY INTERTECHNOLOGY INC - 8-K Filing
- LATTICE SEMICONDUCTOR CORP - 4 Filing
- CENTRUS ENERGY CORP - 8-K Filing
- SAGA COMMUNICATIONS INC - 8-K Filing
- NextBoat Inc. - 8-K Filing
- CIVISTA BANCSHARES, INC. - 8-K Filing
- RF Acquisition Corp II - 10-Q Filing
- ORASURE TECHNOLOGIES INC - 10-Q Filing